Director – Accounting
Revolution Medicines
Director – Accounting
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
Revolution Medicines is seeking an experienced and collaborative accounting leader to serve as the Director of Accounting. This position will lead the Company’s US general ledger accounting function and oversee key aspects of the monthly, quarterly, and annual close processes, including account reconciliations, accruals, prepaids, fixed asset, lease, stock administration and related financial reporting activities.
Reporting to the Executive Director, Accounting, this role will lead and develop a high-performing team, maintain strong internal controls, drive operational excellence, and implement scalable accounting processes to support the Company’s continued growth. The Director will partner closely with Consolidation, Financial Reporting, Technical Accounting, Accounts Payable, Payroll, Procurement, Treasury, Tax, FP&A, Legal, IT, and other business functions.
Key Responsibilities
Lead the General Ledger Accounting function and oversee the monthly, quarterly, and annual financial close processes, ensuring timely, accurate, and complete financial results.
Manage and develop General Ledger Accounting team members by establishing clear performance expectations, providing coaching and feedback, and fostering professional growth.
Oversee journal entries, account reconciliations, accruals, prepaid expenses, fixed assets, intercompany transactions, equity and other general ledger activities.
Ensure balance sheet accounts are appropriately reconciled, reviewed, and supported, with timely resolution of reconciling items.
Partner with Financial Reporting and Technical Accounting teams to support quarterly and annual financial reporting requirements and ensure transactions are recorded in accordance with U.S. GAAP.
Collaborate with Accounts Payable, Payroll, Procurement, Treasury, Tax, FP&A, and other functions to ensure accurate and complete accounting for business activities.
Review accounting results and perform analytical reviews to identify unusual trends, variances, or accounting issues and ensure timely resolution.
Develop, maintain, and strengthen internal controls over general ledger and financial close processes, ensuring compliance with SOX requirements and Company policies.
Partner with the SOX Compliance team on control documentation, testing, remediation activities, user access reviews, and segregation-of-duties assessments for financial systems.
Support internal and external audit activities related to general ledger accounts and close processes, coordinating audit requests and ensuring timely resolution of inquiries.
Establish and monitor key performance indicators and close metrics to improve the timeliness, accuracy, and efficiency of the accounting close.
Identify and implement process improvements, automation opportunities, and system enhancements to increase scalability, strengthen controls, and improve operational efficiency.
Support accounting system implementations, finance transformation initiatives, acquisitions, integrations, and other cross-functional projects as needed.
Maintain accounting policies, procedures, and documentation related to general ledger activities and ensure consistent application across the organization.
Serve as a key accounting partner to business stakeholders, providing guidance on accounting processes, financial controls, and transaction-related matters.
Required Skills, Experience and Education:
Bachelor’s degree in accounting, Finance, Business Administration, or a related field.
10+ years of progressive accounting experience, including significant general ledger and financial close experience and demonstrated people leadership.
Strong knowledge of U.S. GAAP, general ledger accounting, account reconciliations, financial close processes, and internal controls.
Experience working in a public company environment and with SOX compliance requirements.
Demonstrated experience managing complex monthly, quarterly, and annual close processes.
Proven ability to lead, develop, and motivate high-performing accounting teams.
Strong analytical, problem-solving, organizational, and project management skills, with the ability to manage multiple priorities in a fast-paced environment.
Excellent communication and collaboration skills, with the ability to build strong cross-functional relationships and communicate effectively with stakeholders at all levels.
Advanced Microsoft Excel skills and experience with ERP and financial reporting systems.
Preferred Skills:
CPA designation is preferred.
Experience with NetSuite and Coupa systems.
Experience with commercial-stage biopharma companies.
#LI-TS1 #LI-Hybrid
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 211000 - 264000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines